ClinicalTrials.Veeva

Menu

The Incretin Effect in Patients With Chronic Pancreatitis

U

University Hospital, Gentofte, Copenhagen

Status

Completed

Conditions

Chronic Pancreatitis
Type 2 Diabetes Mellitus

Study type

Observational

Funder types

Other

Identifiers

NCT00638573
KA04034

Details and patient eligibility

About

The phenomenon that oral glucose elicits a higher insulin response than does intravenous (iv) glucose, even at identical plasma glucose (PG) profiles (isoglycemia), is called the incretin effect. In type 2 diabetes mellitus (T2DM) the incretin effect has been shown to be markedly reduced or even abolished. It is not known whether the reduced incretin effect in T2DM is a primary event leading to T2DM or if it is merely a consequence of the diabetic state. To answer this question the investigators plan to estimate the incretin effect in 8 patients with secondary diabetes mellitus (DM) to chronic pancreatitis (CP) and compare it to the incretin effect of 8 patients with CP and normal glucose tolerance (NGT). Eight patients with T2DM and 8 healthy control subjects are studied for comparison. The incretin effect is measured by a 50-g oral glucose tolerance test and an isoglycemic intravenous glucose infusion.

Enrollment

32 patients

Sex

All

Ages

18 to 80 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Diagnosis of chronic pancreatitis with secondary diabetes mellitus
  • Diagnosis of chronic pancreatitis with normal glucose tolerance
  • Diagnosis of type 2 diabetes
  • Normal level of hemoglobin
  • Normal level of se-creatinine

Exclusion criteria

  • GAD-65 autoantibodies
  • ICA autoantibodies
  • Albuminuria

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems